resTORbio vs Rejuvenate Bio

resTORbio was a mTOR-pathway geroscience pioneer developing RTB101 to target age-related disease; after its lead Phase 3 trial failed, it reverse-merged into Adicet Bio in 2020 and abandoned its aging program.

Longevity

Rejuvenate Bio

Combination gene therapies targeting the biology of aging and age-related disease in companion animals and humans.

For subscribers

Subscribe for the full comparison

Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.

Already subscribed? Sign in →